These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 15116243)
21. Recent developments in the effects of nitric oxide-donating statins on cardiovascular disease through regulation of tetrahydrobiopterin and nitric oxide. Ma S; Ma CC Vascul Pharmacol; 2014 Nov; 63(2):63-70. PubMed ID: 25139660 [TBL] [Abstract][Full Text] [Related]
22. Differentiated control of deranged nitric oxide metabolism: a therapeutic option in sepsis? Lupp C; Baasner S; Ince C; Nocken F; Stover JF; Westphal M Crit Care; 2013 May; 17(3):311. PubMed ID: 23751085 [TBL] [Abstract][Full Text] [Related]
23. Hyperglycemia-induced platelet activation in type 2 diabetes is resistant to aspirin but not to a nitric oxide-donating agent. Gresele P; Marzotti S; Guglielmini G; Momi S; Giannini S; Minuz P; Lucidi P; Bolli GB Diabetes Care; 2010 Jun; 33(6):1262-8. PubMed ID: 20299485 [TBL] [Abstract][Full Text] [Related]
24. Endothelium negatively modulates the vascular relaxation induced by nitric oxide donor, due to uncoupling NO synthase. Bonaventura D; Lunardi CN; Rodrigues GJ; Neto MA; Vercesi JA; de Lima RG; da Silva RS; Bendhack LM J Inorg Biochem; 2009 Oct; 103(10):1366-74. PubMed ID: 19699534 [TBL] [Abstract][Full Text] [Related]
25. Nitric oxide donors for cardiovascular implant applications. Naghavi N; de Mel A; Alavijeh OS; Cousins BG; Seifalian AM Small; 2013 Jan; 9(1):22-35. PubMed ID: 23136136 [TBL] [Abstract][Full Text] [Related]
26. Exogenous NO Therapy for the Treatment and Prevention of Atherosclerosis. Gori T Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32295055 [TBL] [Abstract][Full Text] [Related]
34. Computational analysis of nitric oxide biotransport to red blood cell in the presence of free hemoglobin and NO donor. Deonikar P; Abu-Soud HM; Kavdia M Microvasc Res; 2014 Sep; 95():15-25. PubMed ID: 24950305 [TBL] [Abstract][Full Text] [Related]
35. Suppressing NADPH oxidase-dependent oxidative stress in the vasculature with nitric oxide donors. Selemidis S Clin Exp Pharmacol Physiol; 2008 Nov; 35(11):1395-401. PubMed ID: 18954334 [TBL] [Abstract][Full Text] [Related]
36. Endothelium-dependent NO-mediated vasodilation in humans is attenuated by peripheral alpa1-adrenoceptor activation. Kamper AM; de Craen AJ; Westendorp RG; Blauw GJ Vasc Health Risk Manag; 2005; 1(3):251-6. PubMed ID: 17319111 [TBL] [Abstract][Full Text] [Related]
37. Nitric oxide and regulation of vascular tone: pharmacological and physiological considerations. McHugh J; Cheek DJ Am J Crit Care; 1998 Mar; 7(2):131-40; quiz 141-2. PubMed ID: 9509227 [TBL] [Abstract][Full Text] [Related]
38. Modulation of nitric oxide pathways: therapeutic potential in asthma and chronic obstructive pulmonary disease. Redington AE Eur J Pharmacol; 2006 Mar; 533(1-3):263-76. PubMed ID: 16466650 [TBL] [Abstract][Full Text] [Related]
39. The role of nitric oxide donors in schizophrenia: Basic studies and clinical applications. Pitsikas N Eur J Pharmacol; 2015 Nov; 766():106-13. PubMed ID: 26435027 [TBL] [Abstract][Full Text] [Related]
40. Pharmacologic profile and therapeutic potential of NCX 4016, a nitric oxide-releasing aspirin, for cardiovascular disorders. Gresele P; Momi S Cardiovasc Drug Rev; 2006; 24(2):148-68. PubMed ID: 16961726 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]